Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli–associated hemolytic uremic syndrome
Pediatric Nephrology · 2025
DOI: 10.1007/s00467-024-06583-3 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Pediatric Nephrology, 2025. Verfasst von Alicia Fayad und 28 weiteren Autor:innen. Beteiligte Einrichtung: Hospital de Niños Ricardo Gutiérrez, Ciudad Autónoma de Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Hemolytic-Uremic Syndrome, Shiga-Toxigenic Escherichia coli, Escherichia coli Infections. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: INMUNOVA SA.
Abstract (Originalsprache)
Background
Shiga toxin-producing Escherichia coli -associated hemolytic uremic syndrome (STEC-HUS) is a severe condition mainly affecting children. It is one of the leading causes of acute kidney injury in the pediatric population. There is no established therapy for this disease. INM004 is an anti-Shiga toxin composed of equine polyclonal antibodies. This study is aimed at assessing the safety, pharmacokinetics, and efficacy of INM004 in pediatric patients with STEC-HUS.
Methods
Phase 2, open-label clinical trial with an historical control arm. Patients in the treatment arm received two doses of INM004. The primary endpoints were the safety profile, pharmacokinetics, and efficacy (dialysis days) of INM004. Secondary endpoints included other kidney and extrarenal outcomes. Propensity score matching was used for efficacy comparisons between arms.
Results
Fifty-seven and 125 patients were enrolled in the treatment and control arm, respectively. After propensity score matching, 52 patients remained in each arm. INM004 was well-tolerated. Eight adverse events were considered possibly related, none of which were serious or severe. In the primary efficacy endpoint, patients of the treatment arm presented a non-statistically significant difference of two dialysis days. On secondary endpoints, non-statistically significant trends toward fewer patients needing dialysis and dialysis for more than 10 days, and shorter time to glomerular filtration rate normalization, were observed favoring the treatment arm.
Conclusions
INM004 showed an adequate safety profile. Efficacy non-statistically significant trends suggesting a beneficial effect in the amelioration of kidney injury were observed. These results encourage the conduction of a phase 3 study of INM004 in pediatric patients with STEC-HUS. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hospital de Niños Ricardo Gutiérrez, Ciudad Autónoma de Buenos Aires, Argentina.
- Hospital Pediátrico Dr. Humberto J. Notti, Mendoza, Argentina.
- Hospital General de Niños Pedro de Elizalde, Ciudad Autónoma de Buenos Aires, Argentina.
- Hospital Interzonal Regional Dr. José Penna, Buenos Aires, Argentina.
- Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina.
- Hospital de Pediatría S.A.M.I.C. Prof. Dr. Juan P. Garrahan, Ciudad Autónoma de Buenos Aires, Argentina.
Förderung
- INMUNOVA SA
Zitieren
APA
Fayad, A., Principi, I., Balestracci, A., Alconcher, L., Coccia, P., Adragna, M., Amoreo, O., Bettendorff, M. C., Blumetti, M. V., Bonany, P., Tonfi, M. L. F., Flynn, L., Ghezzi, L., Montero, J., Ramírez, F., Seminara, C., Suarez, Á., Spizzirri, A. P., Rivas, M., …, & INM004 Study Group (2025). Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli–associated hemolytic uremic syndrome. Pediatric Nephrology. https://doi.org/10.1007/s00467-024-06583-3
Vancouver
Fayad A, Principi I, Balestracci A, Alconcher L, Coccia P, Adragna M, et al. Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli–associated hemolytic uremic syndrome. Pediatric Nephrology. 2025. doi:10.1007/s00467-024-06583-3
BibTeX
@article{Fayad2025,
author = {Fayad, Alicia and Principi, Iliana and Balestracci, Alejandro and Alconcher, Laura and Coccia, Paula and Adragna, Marta and Amoreo, Oscar and Bettendorff, María Carolina and Blumetti, María Valeria and Bonany, Pablo and Tonfi, María Laura Flores and Flynn, Luis and Ghezzi, Lidia and Montero, Jorge and Ramírez, Flavia and Seminara, Claudia and Suarez, Ángela and Spizzirri, Ana Paula and Rivas, Marta and Pichel, Mariana and Zylberman, Vanesa and Spatz, Linus and Massa, Carolina and Valerio, Marina and Sanguineti, Santiago and Colonna, Mariana and Roubicek, Ian and Goldbaum, Fernando and INM004 Study Group, INM004 Study Group},
title = {Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli–associated hemolytic uremic syndrome},
journal = {Pediatric Nephrology},
year = {2025},
doi = {10.1007/s00467-024-06583-3}
}
EUVIMED